Dapagliflozin was well tolerated among patients hospitalized with COVID-19
Click Here to Manage Email Alerts
Among patients hospitalized with COVID-19, dapagliflozin was well tolerated and did not increase risk of AKI in patients, according to data published in the Clinical Journal of the American Society of Nephrology.
Further, dapagliflozin was well tolerated among patients with an eGFR below 60 mL/minute per 1.73² and among those with an eGFR above 60 mL/minute per 1.73².
“The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial was designed to assess the efficacy and safety of the SGLT2 inhibitor dapagliflozin in 1,250 patients with cardiometabolic risk factors acutely hospitalized with COVID-19. The trial demonstrated that dapagliflozin was well tolerated but did not result in a statistically significant risk reduction in the primary outcomes of organ dysfunction or death or improvement in recovery,” Hiddo J. Lambers Heerspink, PhD, PharmD, a professor of clinical trials and personalized medicine and a clinical pharmacologist/trialist in the department of clinical pharmacy and pharmacology at the University Medical Center Groningen in the Netherlands, and colleagues wrote. “We report the effects of dapagliflozin on the composite kidney outcome and AKI, a key component of the composite kidney outcome, in prespecified subgroups of participants by baseline eGFR.”
In a secondary analysis of the DARE-19 trial, which randomized 1,250 patients hospitalized with COVID-19 and cardiometabolic risk factors to treatment with either dapagliflozin or placebo, researchers measured the efficacy and safety of dapagliflozin.
Dual primary outcomes of the DARE-19 trial included time to new or worsened organ dysfunction or death, and a hierarchical composite endpoint of recovery.
At baseline, 18% of patients had an eGFR of less than 60 mL/minute per 1.73 m². Researchers determined the effects of dapagliflozin vs. placebo on the primary prevention outcome, primary recovery outcome and the composite kidney outcome were consistent across eGFR subgroups. Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².
Similarly, the effects of dapagliflozin on AKI were comparable to those in patients with an eGFR of less than 60 mL/minute per 1.73².
“These new data from DARE-19 reinforce the safety of dapagliflozin in acutely ill patients hospitalized with COVID-19 even in those with reduced kidney function who are at particularly high risk of AKI,” Heerspink said in a press release.
“In conclusion, the effects of dapagliflozin compared with placebo in hospitalized participants with COVID-19 on the primary and secondary outcomes were consistent in those with eGFR below or above 60 ml/min per 1.73 m²,” Heerspink and colleagues wrote. “Dapagliflozin was well tolerated and did not increase the risk of AKI in the overall population and in participants with eGFR below or above 60 mL/min per 1.73 m².”
Reference:
- Does the drug dapagliflozin benefit hospitalized patients with COVID-19? https://www.newswise.com/articles/does-the-drug-dapagliflozin-benefit-hospitalized-patients-with-covid-19?sc=cwhr&xy=10007438/?ad2f=1&aid=769566. Published April 28, 2022. Accessed April 28, 2022.
Collapse
Read more about
Click Here to Manage Email Alerts